Skip to main content

Table 4 Correlations between progression-free survival and various clinicopathological factors

From: The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer

 

Univariate analysis

Multivariate analysis

Hazard ratio

95% CI

p-value

Hazard ratio

95% CI

p-value

Location of primary tumor (Rectum)

1.190

0.569-2.486

0.644

   

Histological type (Poorly, Mucinous)

1.711

0.510-5.746

0.385

2.305

0.602-8.825

0.223

Detection of unresectable tumor (Metachronous)

1.069

0.442-2.584

0.882

   

Distant metastasis except peritoneal dissemination (Yes)

1.188

0.280-5.029

0.815

   

Peritoneal dissemination (Yes)

0.727

0.294-1.797

0.490

1.198

0.279-5.142

0.808

The number of organs affected by metastasis (≥2)

0.541

0.241-1.125

0.137

0.273

0.083-0.902

0.033

Pretreatment CEA (>5 ng/ml)

0.787

0.236-2.624

0.696

   

Pretreatment CA19-9 (>37 U/ml)

0.862

0.403-1.845

0.702

   

Molecular targeted therapy (Yes)

0.911

0.449-1.848

0.797

   

Cholinesterase (<235 IU/l)

0.568

0.110-2.941

0.500

   

Cholesterol (<200 mg/dl)

0.852

0.234-3.102

0.809

   

NLR (>2.8)

1.342

0.619-2.911

0.457

1.090

0.434-2.737

0.855

GPS (2)

1.498

0.544-4.123

0.434

1.758

0.489-6.326

0.388

AGR (>1.25)

2.527

1.152-5.545

0.021

2.662

1.085-6.531

0.033

  1. CI: confidence interval, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19–9, NLR: neutrophil to lymphocyte ratio, GPS: Glasgow prognostic score, AGR: albumin to gobulin ratio.